Tejara Capital Ltd Sells 87,874 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Tejara Capital Ltd trimmed its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 36.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,739 shares of the company's stock after selling 87,874 shares during the quarter. Tejara Capital Ltd owned about 0.20% of Trevi Therapeutics worth $633,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after purchasing an additional 6,764 shares during the period. Raymond James Financial Inc. bought a new position in Trevi Therapeutics during the fourth quarter worth $49,000. Intech Investment Management LLC bought a new position in Trevi Therapeutics during the third quarter worth $63,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Trevi Therapeutics in the fourth quarter valued at about $67,000. Finally, SG Americas Securities LLC boosted its position in shares of Trevi Therapeutics by 14.5% in the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company's stock valued at $110,000 after acquiring an additional 3,387 shares during the period. 95.76% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TRVI has been the subject of a number of recent research reports. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their target price for the company from $9.00 to $29.00 in a research report on Monday, March 10th. Oppenheimer boosted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday. B. Riley reissued a "buy" rating and issued a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC reduced their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday. Seven research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $17.56.

Remove Ads

Trevi Therapeutics Price Performance

TRVI stock traded down $0.14 during midday trading on Friday, reaching $6.47. The company had a trading volume of 3,742,537 shares, compared to its average volume of 991,462. The company has a market capitalization of $497.32 million, a price-to-earnings ratio of -14.70 and a beta of 0.90. The stock has a 50 day moving average price of $4.60 and a 200-day moving average price of $3.75. Trevi Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. As a group, research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Transactions at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company's stock, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 24.37% of the company's stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.